{"id":"NCT01297270","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-na√Øve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)","officialTitle":"A Phase III, Randomized, Double Blind and Placebo Controlled Study of Once Daily BI 201335 120 mg for 24 Weeks and BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Patients With Genotype 1 Chronic Hepatitis C Infection.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2011-02-16","resultsPosted":"2015-09-18","lastUpdate":"2015-09-18"},"enrollment":658,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"BI201335","otherNames":[]},{"type":"DRUG","name":"PegIFN/RBV","otherNames":[]},{"type":"DRUG","name":"BI201335","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"PegIFN/RBV","type":"ACTIVE_COMPARATOR"},{"label":"BI 201335 for 24 weeks","type":"EXPERIMENTAL"},{"label":"BI201335 for 12 weeks","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this trial is to evaluate the efficacy and safety of two different treatment regimens with BI 201335, both in combination with PegIFN/RBV) as compared to standard of care (SOC) with PegIFN/RBV alone.","primaryOutcome":{"measure":"Sustained Virologic Response 12 Weeks Post Treatment (SVR12)","timeFrame":"12 weeks post treatment, up to 60 weeks","effectByArm":[{"arm":"Faldaprevir 120mg and PegIFN/RBV","deltaMin":67.9,"sd":null},{"arm":"Faldaprevir 240mg and PegIFN/RBV","deltaMin":64.3,"sd":null},{"arm":"Placebo and PegIFN/RBV","deltaMin":47,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"0.0007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":106,"countries":["United States","Canada","Puerto Rico","South Korea","Taiwan"]},"refs":{"pmids":["27049487"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":262},"commonTop":["Fatigue","Nausea","Rash","Headache","Pruritus"]}}